BACKGROUND: The ICAM-1 +469 A/G polymorphism has been implicated in susceptibility to cancer, but the results were inconclusive. The present meta-analysis aimed to investigate the association between the ICAM-1 +469 A/G polymorphism and cancer risk. METHODS: We searched PubMed, Embase to identify studies that evaluated the association between the ICAM-1 +469 A/G polymorphism and cancer risk. Data were extracted and statistical analysis was performed by using the software Revman 5.1 and STATA 12.0. RESULTS: A total of 14 studies involving 9375 subjects were included. The results suggested that ICAM-1 +469 A/G polymorphism had no associated with cancer risk (OR=0.91, 95% CI: 0.76-1.08, P=0.27 for GG+AG vs. AA). Subgroup analysis by cancer type indicated the there was no associated between this polymorphism and breast cancer (OR=0.91, 95% CI: 0.72-1.15, P=0.43 for GG+AG vs. AA), but it was associated with decreased risk of colorectal cancer (OR=0.59, 95% CI: 0.41-0.85, P=0.005 for GG+AG vs. AA). Subgroup analysis by ethnicity revealed a decreased risk of cancer among Caucasians (OR=0.88, 95% CI: 0.78-0.99, P=0.03 for GG+AG vs. AA) CONCLUSION: The evidence from current meta-analysis doesn't support the ICAM-1 +469 A/G polymorphism as a risk factor for cancer. Further studies are needed to validate these findings.
BACKGROUND: The ICAM-1+469 A/G polymorphism has been implicated in susceptibility to cancer, but the results were inconclusive. The present meta-analysis aimed to investigate the association between the ICAM-1+469 A/G polymorphism and cancer risk. METHODS: We searched PubMed, Embase to identify studies that evaluated the association between the ICAM-1+469 A/G polymorphism and cancer risk. Data were extracted and statistical analysis was performed by using the software Revman 5.1 and STATA 12.0. RESULTS: A total of 14 studies involving 9375 subjects were included. The results suggested that ICAM-1+469 A/G polymorphism had no associated with cancer risk (OR=0.91, 95% CI: 0.76-1.08, P=0.27 for GG+AG vs. AA). Subgroup analysis by cancer type indicated the there was no associated between this polymorphism and breast cancer (OR=0.91, 95% CI: 0.72-1.15, P=0.43 for GG+AG vs. AA), but it was associated with decreased risk of colorectal cancer (OR=0.59, 95% CI: 0.41-0.85, P=0.005 for GG+AG vs. AA). Subgroup analysis by ethnicity revealed a decreased risk of cancer among Caucasians (OR=0.88, 95% CI: 0.78-0.99, P=0.03 for GG+AG vs. AA) CONCLUSION: The evidence from current meta-analysis doesn't support the ICAM-1+469 A/G polymorphism as a risk factor for cancer. Further studies are needed to validate these findings.
Authors: Stefan Kammerer; Richard B Roth; Richard Reneland; George Marnellos; Carolyn R Hoyal; Nathan J Markward; Florian Ebner; Marion Kiechle; Ulrike Schwarz-Boeger; Lyn R Griffiths; Christian Ulbrich; Korbinian Chrobok; Gerhard Forster; Georg M Praetorius; Peter Meyer; Joachim Rehbock; Charles R Cantor; Matthew R Nelson; Andreas Braun Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Christine Schröder; Isabell Witzel; Volkmar Müller; Sylke Krenkel; Ralph M Wirtz; Fritz Jänicke; Udo Schumacher; Karin Milde-Langosch Journal: J Cancer Res Clin Oncol Date: 2011-05-18 Impact factor: 4.553
Authors: Eirini Thanopoulou; George Kotzamanis; Ioannis S Pateras; Nicholaos Ziras; Alexandros Papalambros; Theodoros Mariolis-Sapsakos; Fragiska Sigala; Elizabeth Johnson; Athanassios Kotsinas; Andreas Scorilas; Vassilis G Gorgoulis Journal: Tumour Biol Date: 2012-05-06
Authors: Ravindran Ankathil; Mohd Aminudin Mustapha; Ahmad Aizat Abdul Aziz; Siti Nurfatimah Mohd Shahpudin; Andee Dzulkarnaen Zakaria; Muhammad Radzi Abu Hassan; Kamarul Imran Musa Journal: Asian Pac J Cancer Prev Date: 2019-06-01